The healthcare technology industry arrived at a defining moment in Las Vegas this October. HLTH 2025, drawing more than 12,000 attendees and 400+ speakers to The Venetian Expo Center from October 19-22, showcased an industry undergoing fundamental transformation—not through incremental improvements, but through converging forces that are reshaping care delivery, business models, and the economics of healthcare itself.
From Mark Cuban’s scathing critique of pharmacy benefit managers to the American Medical Association‘s launch of a physician-led AI governance center, from breakthrough artificial intelligence deployments to frank discussions about clinician burnout, HLTH 2025 crystallized three interrelated developments: healthcare AI has moved decisively from pilot projects to operational scale, cost transparency is emerging as a competitive weapon, and the workforce crisis has elevated from HR concern to strategic imperative demanding technological intervention.
What differentiated this year’s gathering from previous HLTH conferences was the shift in tone from aspiration to implementation. The question is no longer whether healthcare organizations will deploy advanced technologies—it’s how quickly they can do so while navigating regulatory complexity, ensuring patient safety, and managing the human dimensions of organizational change.
Artificial Intelligence Transitions from Promise to Production
Healthcare AI investment reached a critical inflection point in 2025, according to the inaugural Menlo Ventures State of AI in Healthcare Report unveiled at HLTH. AI spending in healthcare hit $1.4 billion this year—nearly triple the previous year’s figure—with healthcare organizations adopting AI 2.2x faster than the broader economy. The largest spending categories revealed clear priorities: ambient clinical documentation commanded $600 million, while coding and billing automation accounted for $450 million. Provider organizations represented 75% of total AI spend, underscoring where the operational pain points—and the deployment capital—currently reside.
“There really hasn’t been this type of physician-led approach to innovations in tech. I think tech is going to embrace the AMA’s role because they all want to understand clinical workflow.” — John Whyte, MD, President, American Medical Association
The American Medical Association’s announcement of its Center for Digital Health and AI represented a strategic pivot in how healthcare approaches technology governance. “There really hasn’t been this type of physician-led approach to innovations in tech,” said AMA president John Whyte. “I think tech is going to embrace the AMA’s role because they all want to understand clinical workflow.” The center will work with policymakers and regulators to create healthcare technology standards and advance new technologies—positioning physicians, rather than government agencies or technology companies, as the primary arbiters of clinical AI deployment standards.
GE HealthCare emerged as a major AI player with multiple announcements spanning radiology, diagnostics, and hospital operations. The company unveiled agentic AI projects for radiology aimed at developing the industry’s first agentic AI diagnostic imaging assistant integrated directly into devices. Simultaneously, GE HealthCare announced partnerships with Queen’s Health Systems in Honolulu and Duke Health in Durham to advance hospital operations AI software that will become part of its CareIntellect platform. The software will use AI and predictive analytics to help hospitals manage bed demand, staffing capacity, and equipment downtime—addressing operational challenges that became acute during the pandemic and haven’t abated.
“Now you can really have a common data layer, that’s all the data is structured in a way that you can analyze and plug into,” explained Taha Kass-Hout, GE HealthCare’s global chief science and technology officer. “You can bring more applications, whether that’s on the operations side, on the care delivery side.”
Optum introduced Optum Real, an AI-powered claims processing platform designed to reduce friction between providers and payers during claims submission and reimbursement. The platform connects payers’ core systems and providers’ EHRs to share and receive real-time information on claims-related queries, including prior authorizations, denials, and benefits coverage. “HLTH is important because this is one of the few times you can bring all parties together and have a much more community discussion around the core problems that the system is facing,” said Puneet Maheshwari, SVP and GM of Optum Real.
Other significant AI announcements included OpenEvidence‘s $200 million fundraise to create a “ChatGPT for Medicine” emphasizing trustworthy real-world evidence; Cedar‘s launch of Cedar Cover, an AI-backed solution to combat the potential $63 billion rise in hospital uncompensated care due to Medicaid coverage loss; and Suki‘s expansion of its ambient clinical intelligence solution to automatically generate CPT, E/M, ICD-10, and HCC codes from ambient listening, achieving a 48% reduction in amended encounters.
The proliferation of AI announcements—spanning radiology, pharmacy operations, behavioral health, coding, clinical documentation, and patient engagement—signaled that the pilot phase has concluded. Organizations are now deploying AI for operational impact at scale, with measurable ROI expectations replacing proof-of-concept curiosity.
The Transparency Wars: Cuban Throws Down the Gauntlet
Mark Cuban’s Sunday night keynote discussion delivered one of the conference’s most memorable moments—not for its polish, but for its systematic dissection of healthcare’s economic dysfunction and the industry’s role in perpetuating it. The billionaire entrepreneur and founder of Cost Plus Drugs characterized the industry’s approach to drug pricing as fundamentally broken and called out healthcare leaders for their complicity in maintaining a system that forces Americans to make impossible choices about affording medications.
“We started Cost Plus Drugs from the perspective that we wanted people to be able to go to a website, put in the name of the drug that they had a prescription for, not only see what we were selling it for, but see what our actual cost and markup was, so that they would trust us.” — Mark Cuban, Founder, Cost Plus Drugs
“We started Cost Plus Drugs from the perspective that we wanted people to be able to go to a website, put in the name of the drug that they had a prescription for, not only see what we were selling it for, but see what our actual cost and markup was, so that they would trust us,” Cuban explained. His company’s 15% markup model stands in stark contrast to the opacity of pharmacy benefit managers, which Cuban blamed for “costing everybody hundreds of billions of dollars.”
Cuban announced that Cost Plus Drugs will partner with TrumpRx, the federal drug price transparency initiative set to launch in 2026. TrumpRx will function as a referral platform directing consumers to direct-to-consumer prescription sites like Cost Plus Drugs. “As our volumes go up, our costs go down,” Cuban noted. “The price for patients go down. So for us, it’ll be great, right? It just means more people.”
The entrepreneur’s critique extended beyond PBMs to encompass wholesalers, prior authorization processes, and insurance structures that burden patients with unaffordable deductibles. While acknowledging his preference for free market solutions, Cuban suggested legislation may be necessary to address systemic dysfunction. His message resonated with an audience increasingly frustrated by administrative complexity that adds cost without improving outcomes.
The Cost Plus Drugs-TrumpRx partnership represents a direct challenge to incumbent intermediaries. If successful at scale, the direct-to-consumer model could fundamentally alter pharmaceutical distribution economics, though industry observers remain cautious about whether insurance reimbursement dynamics will shift significantly.
Workforce Crisis Elevates Technology from Tool to Lifeline
The conference’s most sobering moment came during a panel featuring the presidents of the American Medical Association, American Nurses Association, and American Dental Association, who provided unfiltered accounts of the burnout epidemic devastating healthcare professionals across disciplines.
“The not-so-awesome part is when we leave the exam room,” said Bobby Mukkamala, AMA president, describing how bureaucratic demands consume time that should be devoted to patient care. Brett Kessler, American Dental Association president, reported seeing “a massive amount of colleagues who are suffering from burnout, depression, substance abuse disorder, anxiety.”
The statistics presented at HLTH painted a dire picture: 95% of healthcare leaders expressed concern that staffing shortages may impact care quality, while 94% worried about how burnout and disengagement affect patient outcomes. A striking 98% reported observing increased demand for flexible, gig-style work arrangements over the past two years, with 67% noting that burnout and disengagement are rising due to lack of flexibility.
Technology emerged as both symptom and solution in workforce discussions. While administrative burdens from poorly designed health IT systems contribute to burnout, well-implemented AI tools—particularly ambient clinical documentation—offer the possibility of returning time to patient-facing activities. The KLAS Research Top 20 Emerging Solutions list, unveiled at HLTH, explicitly aligned with the Quadruple Aim of improving outcomes, reducing costs, enhancing patient experience, and reducing clinician burnout. Key innovation areas included AI, interoperability, cybersecurity, and compliance technologies.
The workforce crisis has transformed technology adoption from a competitive advantage to a survival requirement. Organizations that can’t reduce administrative burden and offer flexible work arrangements risk losing clinicians to competitors—or losing them from the profession entirely.
GLP-1 Drugs Reshape Weight Management and Care Integration
Weight management emerged as a major conference theme, driven by the explosive growth of GLP-1 drugs and the challenges employers and health plans face in managing both costs and clinical appropriateness. Multiple partnerships announced at HLTH reflected efforts to integrate pharmaceutical interventions with behavioral approaches and cost controls.
Highmark Health announced a partnership with Noom to offer weight management and behavioral health programs to nearly 2 million eligible members starting in 2026. The program leverages AI tools and behavior-science techniques including food logging, body scan technologies, and peer support communities to help members develop sustainable habits. Noom’s GLP-1 management solution will be available to all members taking these medications, working alongside its behavior change program for a holistic approach.
Quantum Health introduced a GLP-1 weight management solution for self-insured employers, powered by Vida Health, that optimizes prescribing patterns and enhances clinical outcomes. The solution focuses on ensuring GLP-1 prescriptions align with clinical need, reducing unnecessary use while supporting employers in managing costs. The program takes a behavior-first approach, beginning with holistic lifestyle changes and less intensive anti-obesity medications—resulting in only 14% of members starting on a GLP-1 compared to the 40-50% typically seen in unmanaged care.
Oscar Health debuted HelloMeno, an Affordable Care Act plan developed in collaboration with Elektra Health specifically for women navigating menopause. The plan offers zero-copay primary care, gynecological and behavioral health visits, as well as no-cost labs, hormone therapy, insomnia medications, and bone density scans.
Knownwell closed a $25 million funding round led by CVS Health Ventures to expand its metabolic health services, which include primary care, nutrition counseling, behavioral health care, and GLP-1 prescribing when clinically appropriate. The startup provides virtual care nationwide as well as in-person care at clinics in Atlanta, Boston, Chicago, and Dallas.
The GLP-1 theme reflected broader healthcare trends: the integration of pharmaceutical, behavioral, and digital interventions; the focus on managing total cost of care rather than individual service costs; and the recognition that sustainable outcomes require addressing multiple factors simultaneously.
Data Interoperability Becomes AI’s Critical Dependency
Multiple HLTH announcements underscored that artificial intelligence’s value realization depends fundamentally on data interoperability. The Fast Healthcare Interoperability Resources (FHIR) standard emerged as the backbone enabling AI deployments, with several major partnerships announced around harmonizing disparate data sources.
InterSystems and Google Cloud announced integration of InterSystems HealthShare with Google Cloud’s ecosystem to deliver a scalable, FHIR-ready data foundation for generative and agentic AI applications. The partnership addresses healthcare IT’s persistent challenge: fragmented and inconsistent data. “AI is transforming healthcare, but it can only succeed when it’s grounded in reliable, actionable data,” said Don Woodlock, head of Global Healthcare Solutions at InterSystems.
Redox and Kno2 announced collaboration to create a combined network connecting nearly 160,000 provider organizations supporting over 40 billion annual transactions. The partnership integrates Kno2’s data movement capabilities with Redox’s integration infrastructure, allowing healthcare organizations to securely share data across formats including HL7, FHIR, and CDA. The platform provides access to federal health information networks via Kno2’s status as a qualified health information network.
Humana and Providence unveiled an initiative leveraging HL7 FHIR standards, Da Vinci Project Implementation Guides, and modern APIs to streamline data exchange between payers and providers. The first phase automates member attribution for Medicare Advantage, reducing manual efforts and enhancing care coordination. “The healthcare industry is overwhelmed by fragmented, inconsistent data formats that make care coordination costly and slow,” said Michael Westover, vice president of population health informatics at Providence.
The consistent message across interoperability announcements: AI tools are only as effective as the data they can access. Organizations investing heavily in AI without simultaneously addressing data harmonization and exchange may find their advanced tools unable to deliver on their promise.
Cybersecurity Threats Accelerate as Attackers Weaponize AI
In the first half of 2025, 343 data breaches affecting 500 or more individuals were reported to the U.S. Department of Health & Human Services, impacting tens of millions of Americans. The shadow of the Change Healthcare ransomware attack—the most damaging cyberattack ever reported in healthcare—loomed over HLTH discussions about security.
“I think attackers are probably using AI faster than we’re using it to defend against it. So they’re moving very quickly, and it’s creating ways for them to just automate things a lot faster.” — Baxter Lee, President, Clearwater
“I think attackers are probably using AI faster than we’re using it to defend against it,” Baxter Lee, president of Clearwater, told attendees. “So they’re moving very quickly, and it’s creating ways for them to just automate things a lot faster, and distribute their ransomware or other exploits in a faster way.”
Lee emphasized that healthcare remains the most targeted industry globally for cyberattacks due to the combination of valuable personal and health information, complex technology environments spanning multiple sites of care, and historically under-resourced security programs. “There’s a reason healthcare is the most targeted industry in the world for a cyber attack, because it’s rife with a lot of vulnerabilities that bad actors are exploiting,” Lee explained. “And a lot of that’s driven by those technology investments.”
Organizations were urged to move beyond compliance checkbox approaches to implement asset-level or system-level analysis of where sensitive data exists, what vulnerabilities threaten those systems, and what controls protect them. The increasing interconnection of healthcare systems—driven by the same interoperability initiatives enabling AI deployment—expands the attack surface that must be defended.
KLAS Research’s inclusion of cybersecurity as a key innovation area in its Top 20 Emerging Solutions reflected the elevation of security from IT concern to boardroom priority. As one presenter noted, cybersecurity has become a patient safety issue, not merely a technical one.
Investment Flows Signal Shifting Priorities
Funding announcements and M&A activity at HLTH revealed where capital is flowing as the industry navigates post-pandemic realities. Smart ring maker Oura announced a previously rumored $900 million fundraise valuing the company at approximately $11 billion, despite questions about when the company might go public.
Town Hall Ventures, the investment company run by former CMS Administrator Andy Slavitt, announced a $440 million new fund. The firm has invested in companies including Ambience Healthcare, Qualified Health, Strive Health, and Thyme Care.
On the M&A front, Machinify closed acquisition of Performant Healthcare for approximately $670 million, expanding its AI-powered payment intelligence platform to serve a broader range of clients including government programs. DocGo acquired SteadyMD, a virtual care platform, while Willow acquired British femtech company Elvie to broaden their combined maternal health device offerings.
Radiology access platforms saw significant investment, with Medmo announcing a $15 million Series A round led by Covera Health, and OneImaging announcing $38 million led by Vy Capital.
The funding patterns reflected themes consistent with the broader conference: operational efficiency through AI, solutions addressing clinician burnout and workforce challenges, women’s health as an emerging investment frontier, and consolidation of fragmented digital health point solutions into more comprehensive platforms.
Women’s Health Gains Long-Overdue Spotlight
HLTH 2025 featured an expanded Women’s Health pavilion and programming track, reflecting growing recognition that women have been historically underserved in research, clinical trials, and funding. From reproductive care to chronic disease management and longevity, innovation is beginning to address decades of gender bias in healthcare.
Transcarent announced expansion of its Experience Store with three new women’s health partners: Maven Clinic, Midi Health, and Progyny, joining existing partners Carrot and Kindbody. The move reflected employers’ increasing focus on comprehensive women’s health benefits as a recruitment and retention tool.
Sessions throughout the conference tackled maternal mental health challenges, the rising costs of fertility care, and how the industry is rethinking clinical research and drug development to account for physiological differences beyond “women aren’t just small men.” The conversations emphasized equity, access, and the market opportunity represented by better addressing women’s healthcare needs across the lifespan.
Convergence Creates Transformation Opportunity—and Risk
The themes that dominated HLTH 2025 don’t exist in isolation—they’re deeply interconnected. AI deployment requires interoperable data infrastructure. Cost transparency efforts depend on technology to expose pricing and automate processes. Addressing the workforce crisis necessitates AI tools that reduce administrative burden. Cybersecurity must protect the increasingly connected systems enabling all these initiatives. Capital flows toward solutions addressing multiple challenges simultaneously.
For healthcare organizations, this convergence creates both opportunity and risk. The technology tools to transform operations, improve outcomes, and control costs are available and increasingly proven. Organizations that can successfully navigate implementation—managing change, ensuring clinician adoption, protecting patient data, and maintaining focus on patient benefit rather than technology for technology’s sake—will gain sustainable competitive advantage.
Conversely, organizations that treat these challenges as separate initiatives to be addressed sequentially, or that underinvest in foundational capabilities like data interoperability and cybersecurity while chasing shiny AI objects, risk falling behind irreversibly.
The question emerging from HLTH 2025 isn’t whether healthcare technology will transform care delivery and business models—the assembled evidence makes clear that transformation is underway. The question is which organizations will lead that transformation, delivering better outcomes at lower cost with improved clinician and patient experiences, and which will struggle to keep pace as the gap between leaders and laggards widens.
For patients—the intended beneficiaries of all this innovation—the promise remains that technology deployed thoughtfully can make healthcare more accessible, more affordable, more personalized, and ultimately more effective. Whether that promise becomes reality for millions of Americans depends on how well healthcare organizations translate the insights and innovations showcased in Las Vegas into operational excellence in communities across the country.
The stakes couldn’t be higher. As multiple speakers noted, healthcare consumes an unsustainable share of GDP while delivering outcomes worse than peer nations at far higher cost. Technology alone won’t solve these systemic challenges, but deployed as part of comprehensive strategies addressing payment models, regulatory frameworks, workforce development, and care delivery redesign, it represents healthcare’s best hope for bending the cost curve while improving what matters most: keeping people healthy and caring for them effectively when they’re not.
HLTH 2025 made clear that the era of incremental improvement has ended. Healthcare technology has reached an inflection point where transformative change becomes possible—and necessary. The industry now enters an implementation phase where execution excellence will separate winners from also-rans, and where patient benefit must remain the ultimate measure of success.
— This original article was created with AI support.
Photo courtesy of HLTH Inc.
